Ozempic and Wegovy make the list of the next 15 drugs in Medicare negotiations: HHS
Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer treatment Calquence, GSK’s chronic obstructive pulmonary disorder (COPD) drug Breo Ellipta, and AbbVie’s antipsychotic medication Vraylar.
How Ozempic is being misused and worsening eating disorders - IN FOCUS: Olivia Petter talks to experts who say that people ...
The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.
Big Pharma is hiding a massive secret about so-called miracle weight-loss drugs like Ozempic – they come with a raft of potentially devastating side effects and can also trap users on an endless merry ...
Biden administration says popular weight loss drugs have been added to Medicare’s list of medications that will be negotiated ...
Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?
Current health news highlights include debates over Medicare pricing for drugs like Ozempic and Wegovy, management shifts ...
The podcast features Numerator Chief Economist Leo Feler, who talks about the potential impact of GLP-1 drugs like Ozempic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback